OBJECTIVES: We aim to perform a systematic literature review on all studies reporting the clinical outcomes of the use of bioresorbable scaffolds (BRS) in different settings of coronary artery disease (CAD). BACKGROUND: BRS are designed to provide early support of the vessel wall postangioplasty, deliver antiproliferative agents to prevent excessive hyperplastic healing responses and finally disappear when no longer required. Emerging data have provided evidence of their use in specific clinical scenarios. METHODS: A comprehensive literature search was performed by 2 independent reviewers utilizing MEDLINE, EMBASE, and Cochrane Library databases. The only 2 CE marked BRS: everolimus-eluting Bioresorbable vascular scaffold ABSORB BVS and the myolimus-eluting DESolve Bioresorbable Coronary Scaffold (BCS) System were included. RESULTS: The studies were categorized into: ST elevation myocardial infarction (STEMI), stable CAD, and all-comers group. Thirty-one studies were included; 8 in

TY - GEN. T1 - Tensile and flexural creep behaviour of self-reinforced polypropylene composites prepared by compression and injection molding. AU - Kmetty, Á. AU - Bakonyi, P.. AU - Vas, M. L.. AU - Bárány, T.. PY - 2012. Y1 - 2012. N2 - In this work the creep behavior of self-reinforced polymer composites (SRPC) were investigated. As matrix material olefin based thermoplastic elastomeric (o-TPE), as reinforcement highly oriented polypropylenes were used. The tested self-reinforced composites were prepared by filament winding with subsequent compression molding and injection molding (from new pre-impregnated pre-product material) technique. On the SRPC creep tests were carried out. The tensile and flexural creep tests were performed by universal tensile machine and dynamic mechanical analyzer (DMA) test. The results revealed that the creep behavior of the self-reinforced materials depended on the matrix material and the reinforcement structure. The highest strain was achieved using woven ...

Endosteal fixation of a ligament graft with a bioabsorbable interference screw installed in a retrograde manner in ACL reconstruction. The bioabsorbable interference screw is insert-molded with a length of suture extending from the distal tip of the screw for pulling the interference screw into the joint and into position for retrograde insertion at the top of the tibial tunnel. The interference screw has a cannulation extending partially through the screw from the leading tip. The cannulation is shaped to receive a correspondingly shaped driver. The driver is inserted into the tibial tunnel to engage the screw. By turning the driver, the interference screw is turned into the tibial tunnel in a retrograde manner. Accordingly, interference fixation of the graft near the tibial plateau is provided, thereby eliminating graft abrasion at the tibial plateau tunnel opening.

This review discusses and summarizes the recent developments and advances in the use of biodegradable materials for bone repair purposes. The choice between using degradable and non-degradable devices for orthopedic and maxillofacial applications must be carefully weighed. Traditional biodegradable devices for osteosynthesis have been successful in low or mild load bearing applications. However, continuing research and recent developments in the field of material science has resulted in development of biomaterials with improved strength and mechanical properties. For this purpose, biodegradable materials, including polymers, ceramics and magnesium alloys have attracted much attention for osteologic repair and applications. The next generation of biodegradable materials would benefit from recent knowledge gained regarding cell material interactions, with better control of interfacing between the material and the surrounding bone tissue. The next generations of biodegradable materials for bone repair and

This is the first case in the literature describing the V-stenting technique using ABSORB (Abbott Vascular, Santa Clara, California) bioresorbable everolimus-eluting scaffolds (BVS) for the treatment of a left main coronary artery (LMCA) true bifurcation lesion. A 66-year-old woman presented with symptoms of stable angina. A diagnostic angiogram revealed a significant mid-left anterior descending artery (LAD) lesion. After successful implantation of 2 BVS in the mid-LAD, a control angiogram showed haziness extending from distal LMCA into LAD ostium (Medina 0.1.1), likely representing plaque disruption (Fig. 1-I). Due to the fact that the lesions extended in both the LAD and left circumflex artery, we decided to perform V-stenting. A 3.5 × 12-mm BVS (LMCA-LAD) and a 3.5 × 18-mm BVS (LMCA-left circumflex artery) were simultaneously deployed followed by final kissing-balloon inflation. An excellent final angiographic result was achieved (Fig. 1-III). Post-procedural intravascular ultrasound and ...

Spearheaded by principal investigator Stéphane Cook, MD, University and Hospital Fribourg, Switzerland, the trial sought to assess the efficiency and safety of the Absorb bioresorbable vascular scaffold and its ability to reduce long-term complications such as neoatherosclerosis and very late stent thrombosis. Testing the device against the EES and BES, the trial divided its study population into respective treatment groups (BVS, n=78; EES, n=80; BES, n=80).. Clinical outcomes at nine months showed that the BVS arm experienced nine device-oriented major adverse cardiac events, while the EES and BES arms had 11 and four respectively. Results also showed the BVS arm experienced 21 patient-oriented major adverse cardiac events (all-cause mortality, myocardial infarction, revascularization, target vessel revascularization), while EES and BES had 26 and 15 respectively. Cook and colleagues note that in-segment LLL was slightly but significantly higher in BVS compared to EES/BES, and that a possible ...

Plaster of Paris is employed to form implants as well as a bioresorbable scaffold for implants and bone repair in animals. In bone repair, the plaster is mixed with a non-bioresorbable calcium source,

Mountain View, Calif.-based Amaranth Medical announced a $20 million Series B funding round in support of development of the companys flagship Fortitude bioresorbable scaffold, a device-based treatment for coronary artery disease.. Amaranth plans to use the funds to further progress in clinical trials in hopes of winning CE Mark approval in the European Union, according to a company statement. ...

TY - JOUR. T1 - Determination of bioceramic filler distribution and porosity of self-reinforced bioabsorbable composites using micro-computed tomography. AU - Niemelä, T.. AU - Aydogan, D. B.. AU - Hannula, M.. AU - Hyttinen, J.. AU - Kellomäki, M.. PY - 2011/5/1. Y1 - 2011/5/1. N2 - A micro-computed tomography (μ-CT) image analysis was used in the micro-structural analysis of self-reinforced bioabsorbable osteoconductive composites. The composites studied were known to have a porous structure, but the total porosity of these composites had not been measured due to lack of interconnected pores. The micro-structure of the composites studied has previously been estimated using scanning electron microscopy (SEM). This yielded a very rough estimation of the micro-structure based only on the surface estimate and thus more precise μ-CT image analyses of the total porosity and volumetric filler distribution were done. The present study was performed on five different composites manufactured with ...

Ultrasonically Assisted Anchoring of Biodegradable Implants for Chevron Osteotomies - Clinical Evaluation of a Novel Fixation Method

The invention provides biodegradable implants for treating sinusitis. The biodegradable implants have a size, shape, density, viscosity, and/or mucoadhesiveness that prevents them from being substantially cleared by the mucociliary lining of the sinuses during the intended treatment period. The biodegradable implants include a sustained release therapeutic, e.g., an antibiotic, a steroidal anti-inflammatory agent, or both. The biodegradable implants may take various forms, such as rods, pellets, beads, strips, or microparticles, and may be delivered into a sinus in various pharmaceutically acceptable carriers.

Scaffolds for tissue engineering prepared from biocompatible, biodegradable polymer-based, lighter than or light as water microcarriers and designed for cell culturing in vitro in a rotating bioreacto

Self-reinforced poly(ethylene terephthalate) composite laminates were manufactured from fabric using a hot press. Fabric was either allowed to shrink or exposed to stretching during different phases of the manufacturing process. Composite macrostructure, crimp, was investigated and results showed that shrinkage affects fibre crimp more than stretching does. Mechanical tests showed that shrinkage do not significantly affect mechanical properties while stretching fabric by 10% during heating results in 50% increase in tensile stiffness. The lack of correlation between crimp and mechanical properties indicates that mechanical properties for self-reinforced poly(ethylene terephthalate) composites are dominated by their microstructure, molecular orientation, which may be affected by the manufacturing process.. ...

BACKGROUND: The Absorb bioresorbable vascular scaffold (BVS) completely resorbs within 3 years after coronary artery implantation. The safety and effectiveness of BVS through this critical 3-year period have not been characterized.. METHODS: We performed an individual-patient-data pooled meta-analysis of the 4 randomized ABSORB trials in which 3389 patients with coronary artery disease were randomly assigned to everolimus-eluting Absorb BVS (n=2164) or cobalt-chromium everolimus-eluting stents (n=1225). The primary efficacy outcome measure was target lesion failure (cardiac mortality, target vessel myocardial infarction, or ischemia-driven target lesion revascularization), and the primary safety outcome measure was device thrombosis.. RESULTS: BVS compared with cobalt-chromium everolimus-eluting stents resulted in higher 3-year rates of target lesion failure (11.7% versus 8.1%; risk ratio [RR], 1.38; 95% confidence interval [CI], 1.10-1.73; P=0.006), driven by greater target vessel myocardial ...

The absence of clinical restenosis in the first major trial of metallic drug-eluting stents (DES) (1) elicited unbridled enthusiasm among interventional cardiologists. However, it did not take long to realize that, although DES were a marked improvement over bare-metal stents (2), they were not perfect. Specifically, McFadden and et al. (3) reported a new complication in 4 patients, late stent thrombosis occurring after discontinuation of dual antiplatelet therapy (DAPT) (3). Since then, we have learned that target lesion-related failures after 1 year (including restenosis as well as thrombosis) occur at a frequency of 2% to 3% per year for all permanent metallic stents, a rate that may continue for 20 years or longer (4,5). The mechanisms contributing to these stent-related failures are multifactorial and include incomplete endothelialization, persistent inflammation, vessel straightening and compliance mismatch, strut fracture, neoatherosclerosis, and others. Bioresorbable vascular scaffolds ...

Background: After the bioresorbable PLLA-based vascular scaffold (Absorb BVS) was taken from the market due to its high adverse event rates, a magnesium-based scaffold (Magmaris) was introduced.Objective: To compare the acute performance of the sirolimus-eluting magnesium alloy Magmaris scaffold with that of the novolimus-eluting PLLA-based DESolve scaffold in terms of appropriate scaffold deployment using optical coherence tomography (OCT).Methods and Results: Data from the final OCT pullback of 98 patients were included (19 Magmaris, 79 DESolve) and analyzed at 1-mm intervals. The following indices were calculated: mean and minimal area, residual area stenosis, incomplete strut apposition, tissue prolapse, eccentricity index, symmetry index, strut fracture, and edge dissection. OCT showed a minimum lumen area for Magmaris vs. DESolve of 6.6 ± 1.6 vs. 6.0 ± 1.9 (p = 0.06). Scaffolds with residual area stenosis |20% were predominantly seen in the DESolve group (15.8 vs. 46.8%; p = 0.01). The mean

This is the first prospective study to evaluate the economic outcomes associated with the use of a bioresorbable scaffold versus a conventional DES among patients undergoing PCI. In this randomized trial involving 2,008 patients with stable and unstable coronary artery disease, we found that the use of the Absorb scaffold was associated with slightly higher procedural costs and index hospitalization costs when compared with the Xience stent. Although the total 1-year costs were also numerically higher in the Absorb group, the cost difference was small (approximately $350/patient) and was not significant. Taken together with clinical outcomes demonstrating statistical noninferiority of the Absorb scaffold to the Xience DES, these findings demonstrate roughly comparable clinical and economic outcomes with these 2 devices within 1 year (assuming a $100 per device price difference). However, these results remain uncertain at present, because the ABSORB III trial was underpowered to exclude small ...

TY - JOUR. T1 - Handedness of Twisted Lamella in Banded Spherulite of Chiral Polylactides and Their Blends. AU - Wang, Hsiao Fang. AU - Chiang, Chen Hung. AU - Hsu, Wen Chun. AU - Wen, Tao. AU - Chuang, Wei Tsung. AU - Lotz, Bernard. AU - Li, Ming Chia. AU - Ho, Rong Ming. PY - 2017/7/25. Y1 - 2017/7/25. N2 - Banded spherulite resulting from lamellar twisting due to the imbalanced stresses at opposite fold surfaces can be formed by isothermal crystallization of chiral polylactide and its blends with poly(ethylene glycol) (PEG). Using a polarized light microscope, the handedness of the twisted lamella in banded spherulite is determined. With the same growth axis along the radial direction as evidenced by wide-angle X-ray diffraction (WAXD) for isothermally crystallized samples at different temperatures, the twisted lamellae of chiral polylactides (poly(l-lactide) (PLLA) and poly(d-lactide) (PDLA)) display opposite handedness. The split-type Cotton effect on the C = O stretching motion of ...

Bioresorbable drug-eluting scaffolding appears to be safe and effective in patients with iliac and femoral artery lesions, based on six-month results in the first-in-man ESPRIT trial presented Jan. 22 at the International Symposium on Endovascular Therapy in Miami Beach, Fla.

The DESappear study is an important milestone in the pursuit of bringing innovative therapies with state-of-the-art bioresorbable technologies to treat a vulnerable population of patients with peripheral arterial disease, said Bosiers. I am excited to be working with Akesys Medical with the goal to bring this vital product to the clinic.. DESappear investigator Andrew Holden, director of Interventional Services at Auckland City Hospital and associate professor of Radiology at Auckland University School of Medicine, implanted the first Prava in a 66-year-old patient with 45mm of disease in the mid-superficial femoral artery and 80% blockage.. The diabetic patient with short distance leg claudication demonstrated 0% residual stenosis following the procedure with the Prava scaffold and has recovered well, said Holden. The Prava scaffolds easy deliverability for treatment and its excellent structural support to the vessel without leaving behind a permanent metallic implant has the potential ...

Discover Fantom, REVAs drug-eluting bioresorbable coronary scaffold: a thin strut, x-ray visible BRS made from Tyrocore, a tyrosine-derived polymer.

Novel methods for assessing the electrochemical and micromechanical performance of modular tapers were evaluated, and self-reinforced composite materials were developed for their potential to prevent the onset of mechanically assisted corrosion in modular taper devices. A study of the seating and taper locking mechanics of modular taper samples was conducted, and the effect on taper engagement strength of seating load, loading rate, taper moisture, and taper design/material combination was studied. The load-displacement behavior was captured during seating, and the subsequent pull off load was correlated to seating displacement, seating energy, and seating load. The primary factor affecting taper engagement strength was seating load, and loading rate and design/material factors did not have a significant impact on the quality of the taper engagement. Next, the effect of variation of 7 different design, material, and surgical factors on the fretting corrosion and micromechanical behavior during

Vascular response after coronary angioplasty varies according to the technique. Acute response after balloon angioplasty is characterized by luminal gain in most cases, although dissection can occur during the procedure, putting coronary artery patency at risk. Arterial elastic recoil sometimes follows this acute luminal gain, resulting in some degree of restenosis.. Bare-metal stents represented a great advance because they overcame these 2 main limitations of balloon angioplasty. However, vascular damage created by bare-metal stent implantation can result in intense tissue proliferation around the struts, leading to another form of restenosis: proliferative rather than mechanical recoil. Drug-eluting stents (DES) were developed to overcome this limitation by incorporating antiproliferative drugs. First-generation DES changed the post-stenting healing process; however, the lack of coverage of a substantial amount of DES struts was shown to contribute substantially to stent thrombosis ...

Researchers for the DESolve study recommended testing the latest iteration of the device in a larger group of patients, based on results of a first-in-man-study published in the December issue of the Journal of the American College of Cardiology: Cardiovascular Interventions.

Corbion N.V, Evonik Industries Ag, Kls Martin Group, Poly-Med and Foster Corporation are some of the prominent players profiled in MRFR Analysis and are at the forefront of competition in the Global Bioresorbable Polymers Market.. Bioresorbable Polymers Market - Overview. Bioresorbable Polymers are gaining a huge traction over the past decade, owing to its augmented use in the Controlled drug delivery matrix. Get Free Sample Request @ https://www.marketresearchfuture.com/sample_request/969. Consecutively, the global Bioresorbable Polymers Market is exponentially gaining momentum attributed to the burgeoning Healthcare sector. Nowadays, people are inclined towards avoiding surgeries as long as possible and instead prefer controlled drug delivery matrix. Implants made from Bioresorbable Polymers dont need another operation to take implants out. Bioresorbable Polymers get completely biodegraded in the human body without causing any harm minimizing post-surgery risk to the patient and thus ...

This website uses cookies to improve your experience while you navigate through the website. Out of these cookies, the cookies that are categorized as necessary are stored on your browser as they are essential for the working of basic functionalities of the website. We also use third-party cookies that help us analyze and understand how you use this website. These cookies will be stored in your browser only with your consent. You also have the option to opt-out of these cookies. But opting out of some of these cookies may have an effect on your browsing experience ...

Initial Experience of Bioabsorbable Polymer Everolimus-Eluting Synergy Stents in High-Risk Patients Undergoing Complex PCI With Early Discontinuation of Dual-Antiplatelet Therapy

To gain insight into the comparative clinical efficacy of the Orsiro bioabsorbable polymer stent versus an everolimus-eluting durable polymer stent ...

The invention provides biodegradable implants for treating sinusitis. The biodegradable implants have a size, shape, density, viscosity, and/or mucoadhesiveness that prevents them from being substant

Global Bioresorbable Polymers Market is driven by the increase in patient comfort brought about by Bioresorbable polymers, The growing demand for bioresorbable polymers for drug delivery is another key aspect of the trajectory of the global bioresorbable polymers market

Read Supramolecular structure of polylactides: Influence of the crystallization parameters on the structure of film samples, Russian Journal of Applied Chemistry on DeepDyve, the largest online rental service for scholarly research with thousands of academic publications available at your fingertips.

Bangalore S, Bezerra HG, Rizik DG, Armstrong EJ, Samuels B, Naidu SS, Grines CL, Foster MT, Choi JW, Bertolet BD, Shah AP, Torguson R, Avula SB, Wang JC, Zidar JP, Maksoud A, Kalyanasundaram A, Yakubov SJ, Chehab BM, Spaedy AJ, Potluri SP, Caputo RP, Kondur A, Merritt RF, Kaki A, Quesada R, Parikh MA, Toma C, Matar F, DeGregorio J, Nicholson W, Batchelor W, Gollapudi R, Korngold E, Sumar R, Chrysant GS, Li J, Gordon JB, Dave RM, Attizzani GF, Stys TP, Gigliotti OS, Murphy BE, Ellis SG, Waksman R. The State of the Absorb Bioresorbable Scaffold: Consensus From an Expert Panel. JACC Cardiovasc Interv. 2017 12 11; 10(23):2349-2359 ...

Achievement of final in-scaffold/stent residual stenosis of less than 30% by QCA (by visual estimation if QCA unavailable) with successful delivery and deployment of at least one assigned scaffold/stent at the intended target lesion and successful withdrawal of the delivery system for the target lesion without the occurrence of cardiac death, target vessel MI or repeat TLR during the hospital stay (maximum of 7 days). In dual target lesion setting, both lesions must meet clinical procedure success criteria to have a patient level procedure success.. Acute success (device success and procedure success) was determined based on the device randomized while the Per-Treatment-Evaluable Population (PTE) analysis must be based on the device actually received. Hence, device success and procedure success were provided for the ITT population only. ...

Wykrzykowska et al report a randomized clinical trial of metallic stent v bioresorbable vascular scaffold in routine percutaneous coronary intervention. They found significantly higher risk of device thrombosis with BVS. The editorial is available here. Summary BACKGROUND Bioresorbable vascular scaffolds were developed to overcome the shortcomings of drugeluting stents in percutaneous coronary intervention (PCI). We…

First-of-its-kind medical device, Absorb bioresorbable vascular scaffold opens clogged arteries to restore blood flow, then gradually dissolves in the body.. Loma Linda University Medical Center - Murrieta (LLUMC-Murrieta) announced that it is among the first hospitals in Southern California to begin using fully dissolving stents, a technology designed to restore blood vessels without leaving residual metal behind, as has been the case with conventional metal stents.. The Absorb Bioresorbable Vascular Scaffold stent is a technology manufactured by Abbott Vascular, a division of Abbott Laboratories located in Temecula, CA, just a few miles away from the hospital.. This is a major milestone for the Cardiac Services program at Loma Linda University Medical Center- Murrieta, said Dr. Niraj V. Parekh, Cath Lab Medical Director. We are now able to offer patients with coronary artery disease a new treatment option that literally disappears over time.. Dr. Steve Jin, an Interventional Cardiologist ...

/PRNewswire/ -- According to a new market research report Bioabsorbable Stent/Bioresorbable Scaffold Market by Material (Polymer/Metal), Absorption Rate...

While coronary stents have been used to treat CAD since the 1990s, a new stent technology - the SYNERGY Bioabsorbable Polymer Drug-Eluting Stent System - was approved by the U.S. Food and Drug Administration in October 2015, and is the first and only bioabsorbable polymer stent available in the U.S. Unlike traditional drug coated stents that feature permanent polymer coatings known to cause inflammation within the vessels, the SYNERGY stents coating dissolves and disappears after the stents drug has been released. This action enables quick healing of the blood vessel, leaving only the metal part of the stent in the body; ensuring that the blood vessel remains propped open and can deliver blood to the heart for life.. ...

- Clinical Results from 101 Patients Show Low MACE Rate, No Blood Clots and Low Late Loss - In a Sub-Analysis, Nearly All Patients Vessels Assessed for Vasomoto

Bioabsorbable vascular scaffolds are naturally dissolving scaffolds used in the treatment of coronary artery disease (CAD). These are the latest...

In medicine, a stent is any device which is inserted into a blood vessel or other internal duct in order to expand the vessel to prevent or alleviate a blockage. Traditionally, such devices are fabricated from metal mesh and remain in the body permanently or until removed through further surgical intervention. A bioresorbable stent, (also called biodegradable, or naturally-dissolving) serves the same purpose, but is manufactured from a material that may dissolve or be absorbed in the body. The use of metal drug-eluting stents presents some potential drawbacks. These include a predisposition to late stent thrombosis, prevention of late vessel adaptive or expansive remodeling, hindrance of surgical revascularization, and impairment of imaging with multislice CT. To overcome some of these potential drawbacks, several companies are pursuing the development of bioresorbable or bioabsorbable stents. Like metal stents, placement of a bioresorbable stent will restore blood flow and support the vessel ...

Drug-eluting stents (DES) have reached a high safety and efficacy profile, becoming the best option for percutaneous coronary interventions (PCI) based revascularization. However, despite their optimal performance, a few concerns remain regarding their use, mainly due to permanent caging of the vessels and its consequences, first of all late stent thrombosis (ST). Bioresorbable scaffolds (BRS) aim to overcome these issues. The results achieved in randomized controlled trials (RCT) by the first generation of poly-L-lactic acid (PLLA) based scaffolds were promising at 1 year, but the first long term reports (albeit flawed by non-optimal implantation technique) have been disappointing, showing, for instance, an increased risk of ST and target vessel myocardial infarction (TV-MI ...

Review the clinical data from REVAs FANTOM II trial for the latest evidence about bioresorbable scaffolds (BRS, BVS, bioabsorbable scaffolds).

Summary. GlobalDatas Medical Devices sector report, Bioabsorbable Stents - Medical Devices Pipeline Assessment, 2015″ provides an overview of Bioabsorbable Stents currently in pipeline stage.. The report provides comprehensive information on the pipeline products with comparative analysis of the products at various stages of development. The report reviews major players involved in the pipeline product development. It also provides information about clinical trials in progress, which includes trial phase, trial status, trial start and end dates, and, the number of trials for the key Bioabsorbable Stents pipeline products.. Browse Full Report With TOC at ...

Summary. GlobalDatas Medical Devices sector report, Bioabsorbable Stents - Medical Devices Pipeline Assessment, 2015″ provides an overview of Bioabsorbable Stents currently in pipeline stage.. The report provides comprehensive information on the pipeline products with comparative analysis of the products at various stages of development. The report reviews major players involved in the pipeline product development. It also provides information about clinical trials in progress, which includes trial phase, trial status, trial start and end dates, and, the number of trials for the key Bioabsorbable Stents pipeline products.. Browse Full Report With TOC at ...

A biodegradable, bioabsorbable medical device with a coating for capturing progenitor endothelial cells in vivo and delivering a therapeutic agent at the site of implantation. The coating on the medical device is provided with a biabsorbable polymer composition such as a bioabsorbable polymer, copolymer, or terpolymer, and a copolymer or terpolymer additive for controlling the rate of delivery of the therapeutic agent.

Improved aerodynamically light particles for drug delivery to the pulmonary system, and methods for their synthesis and administration are provided. In a preferred embodiment, the aerodynamically light particles are made of biodegradable material and have a tap density of less than 0.4 g/cm3 and a mass mean diameter between 5 μm and 30 μm. The particles may be formed of biodegradable materials such as biodegradable polymers. For example, the particles may be formed of a functionalized polyester graft copolymer consisting of a linear α-hydroxy-acid polyester backbone having at least one amino acid group incorporated therein and at least one poly(amino acid) side chain extending from an amino acid group in the polyester backbone. In one embodiment, aerodynamically light particles having a large mean diameter, for example greater than 5 μm, can be used for enhanced delivery of a therapeutic agent to the alveolar region of the lung. The aerodynamically light particles incorporating a therapeutic agent

Improved aerodynamically light particles for drug delivery to the pulmonary system, and methods for their synthesis and administration are provided. In a preferred embodiment, the aerodynamically light particles are made of biodegradable material and have a tap density of less than 0.4 g/cm 3 and a mass mean diameter between 5 μm and 30 μm. The particles may be formed of biodegradable materials such as biodegradable polymers. For example, the particles may be formed of a functionalized polyester graft copolymer consisting of a linear α-hydroxy-acid polyester backbone having at least one amino acid group incorporated therein and at least one poly(amino acid) side chain extending from an amino acid group in the polyester backbone. In one embodiment, aerodynamically light particles having a large mean diameter, for example greater than 5 μm, can be used for enhanced delivery of a therapeutic agent to the alveolar region of the lung. The aerodynamically light particles incorporating a therapeutic

Define Magnesium alloy. Magnesium alloy synonyms, Magnesium alloy pronunciation, Magnesium alloy translation, English dictionary definition of Magnesium alloy. n. Symbol Mg A light, silvery-white, moderately hard metallic element that in ribbon or powder form burns with a brilliant white flame. Obtained chiefly...

Fingerprint Dive into the research topics of Stent thrombosis with bioabsorbable polymer drug-eluting stents: insights from the Food and Drug Administration database. Together they form a unique fingerprint. ...

The introduction of drug-eluting stents (DES) in the treatment of coronary artery disease has led to a significant reduction in morbidity. However, the first generation of these devices had no positive impact on the mortality after PCI (compared to bare metal stents), which was greatly attributed to a somewhat increased incidence of late and very late stent thrombosis. Concerns about the role of durable polymers as a potential trigger of inflammation and finally adverse events also led to the development of DES with biodegradable coatings, which leave after degradation of the coating only a bare metal stent in the vessel wall that does not induce an inflammatory response. While such biodegradable polymer DES are increasingly used in clinical practice, there is no data available from head-to-head comparisons between biodegradable and contemporary third generation durable polymer DES ...

magnesium alloy pipe, You can Buy good quality magnesium alloy pipe , we are magnesium alloy pipe distributor & magnesium alloy pipe manufacturer from China market.

magnesium alloy slab, You can Buy good quality magnesium alloy slab , we are magnesium alloy slab distributor & magnesium alloy slab manufacturer from China market.

magnesium alloy panhead Manufacturers Directory - find 12 magnesium alloy panhead from magnesium alloy panhead online Wholesalers for your sourcing needs from China.

Microstructural simulation of friction stir welding using a …. Microstructure evolution model The microstructural evolution during FSW of AZ91 magnesium alloy is simulated using the coination of CA and LJ methods in Deform-3D software which are coupled to the thermo-mechanically, rigid-viscoplastic FEM model of FSW. Microstructure and interfacial reactions of soldering …. The U.S. Department of Energys Office of Scientific and Technical Information @article{osti_22066166, title = {Microstructure and interfacial reactions of soldering magnesium alloy AZ31B}, author = {Liu , E-mail: [email protected] and Zhonghui, Wu}, abstractNote = {In this paper, economic and innoxious solder alloys with low melting temperature were designed for AZ31B.. Microstructure characterization of LAE442 magnesium …. The magnesium alloy LAE442 was processed by extrusion and equal channel angular pressing (ECAP) to achieve ultrafine grained microstructure. Detailed characterization of the microstructure was ...

Xian Yuechen Metal Products is prominent Manufacturer, Exporter and Supplier of Magnesium Alloy Billet based in China. Send us your requirement details of Magnesium Alloy Billet

Emergence of Biodegradable Materials to Encourage Global Bone Repair Materials Markets Growth - Press Release by MarketResearchReports.biz

News and information on minimally invasive coronary disease therapies, covering valvular, structural, radial access, chronic total occlusion, and imaging issues.

PubMed Central Canada (PMC Canada) provides free access to a stable and permanent online digital archive of full-text, peer-reviewed health and life sciences research publications. It builds on PubMed Central (PMC), the U.S. National Institutes of Health (NIH) free digital archive of biomedical and life sciences journal literature and is a member of the broader PMC International (PMCI) network of e-repositories.

TY - JOUR. T1 - Structure homogeneity and low-temperature micromecanical properties of ultrafine-grained magnesium alloy AZ31. AU - Estrin, Y. Z.. AU - Fomenko, L. S.. AU - Lubenets, S. V.. AU - Rusakova, A. V.. PY - 2011/6. Y1 - 2011/6. N2 - The degree of microstructure homogeneity for an ultrafine-grained (UFG) AZ31 magnesium alloy obtained by special thermomechanical treatment including four passes of equal-channel angular pressing (ECAP, Route Bc) was studied by the microindentation method. The defect structure of the UFG alloy was found to be reasonably homogeneous. The texture associated with ECAP results in lower values of mi-crohardness measured on the plane normal to the extrusion axis as compared to those on a plane containing the axis, and also in some dependence of microhardness on the location of the indent on the billet surface. The microhardness of the initial coarse grained alloy was close to that of the UFG samples measured on the plane normal to the extrusion axis. The tensile ...

The process progress for magnesium alloy surface treatment technology include conversion coating, anodizing, micro-arc oxidation, electrochemical plating, ion implantation etc was summarized. The development trends for magnesium alloy surface treatment were analyzed.

China Magnesium Alloy Frame Kids Balance Bike - GS-003-Tr02m1, Find details about China Kids Balance Bike, Kids Running Bike from Magnesium Alloy Frame Kids Balance Bike - GS-003-Tr02m1 - Ningbo Yinzhou Wideland Sports Co., Ltd.

The Promus ELITE Stent System builds on the proven outcomes of almost 10,000 patients in 11 clinical trials of permanent polymer coronary stents

A method for the production of a lamellar reflective polymeric body is provided and includes the steps of providing a first stream of a first heat plastified polymeric material and a second stream of a second heat plastified polymeric material, and encapsulating discrete portions of the first polymeric material in the second polymeric material by coextruding the polymeric materials to form a plurality of ribbon-like layers of the first polymeric material within a matrix of the second polymeric material to form the reflective polymeric body. The layers of the first polymeric material are arranged to have their major interfaces aligned substantially parallel to the major surfaces of the body such that at least 30% of light incident on the body is reflected. The ribbon-like layers may be further divided into a series of platelet-like layers to produce layers which are discontinuous in all major planar dimensions by passing the ribbon-like layers through a reciprocating feed plate or valve.

Column 802. five or 10 minutes. It seems absurd that we use the container for those five or 10 minutes but that it will lie in or on the ground for five or 50 years. The third argument relates to disposal. Biodegradable materials are less stable as landfill materials where future buildings may be constructed. That is a short-sighted argument. The fact is that we are desperately short of landfill sites in this country. We cannot go on for ever with that method of disposal. We need to look at alternatives. Primarily, that will be incineration, for which biodegradable materials are well suited. Advances in science now mean that totally biodegradable materials are available, or will soon become available. They are often made of plant material. Paper and cardboard are long established but usually need to be coated with a film to ensure adequate protection of the food. Such a film is usually a plastic, such as polythene, which is not biodegradable. Furthermore, it prevents penetration by water and ...

Bioabsorbable (PLLA) Wedge Interference Screws,The Stryker Bioabsorbable Wedge Interference Screw is made of Poly-L Lactic Acid (PLLA). The patented wedge design makes it perfect for cruciate reconstruction and is indicated for BTB and soft tissue grafts.,medicine,medical supply,medical supplies,medical product

Last night news began circulating on Twitter that Abbotts Absorb BVS (Bioresorbable Vascular Scaffold) was being withdrawn from the European market. This information was prompted by several physicians posting on Twitter a March 31 Urgent Field Safety Notice/Physician Advisory letter from Abbott addressed to Valued Abbott Vascular Customer.. A number of news sources, including this one, posted articles and tweets to the effect that the Absorb was being taken off the commercial markets and, as the letter stated, Effective May 31, 2017, the device will only be available in clinical register setting at select sites/institutions that will play a pivotal role in the monitoring of this technology until Summer 2018 at which time the situation will be reviewed.. This morning Abbott reacted to this initial flurry of reports that they had pulled the Absorb with some clarification: specifically that the Absorb is NOT being pulled from the market and still retains the CE Mark. An Abbott spokesperson ...

Why are bioresorbable scaffolds so exciting? Simply because they fulfil the task of scaffolding the artery wall during the healing period, and thereafter vanish. In other words, their lifetime is adjusted to the healing process, thus avoiding any risk of causing a new disease (eg, late thrombosis, in-stent restenosis, or neoatherosclerosis) as can happen with permanent stents. Permanent stents do a perfect scaffolding job, but remain in place when they are no longer necessary, leading to a foreign body reaction with complications.

Indias National Pharmaceutical Pricing Authority is slated to revisit its decision to impose price caps on coronary stents in February of 2018 and it is looking for input from manufacturers, the agency said in a statement last week.. The NPPA capped prices for drug-eluting stents and bioresorbable scaffolds in February this year, while also cutting the prices for all coronary stents by as much as 85%. The move was largely criticized by companies within the medical device industry.. Abbott(NYSE:ABT) announced earlier this month that it wont introduce its next-gen drug-eluting stent, Xience Alpine, in the Indian market due to the price caps. Boston Scientific (NYSE:BSX) is looking pull its Synergy device from the market for the same reason.. In October, AdvaMed filed a petition with the U.S. Trade Representative seeking to suspend Generalized System of Preferences benefits to India over the price cap issue.. The GSP is a preferential trade program used by the U.S. to give duty-free treatment for ...

2000 The American Ceramic Society. Manuscript No. 189354. Received May 7, 1999; approved June 22, 2000. Based in part on the thesis submitted by M. A. Boling-Risser for the Ph.D. degree in materials science and engineering, Northwestern University, Evanston, Illinois, 1998. This research was supported by the U.S. Department of Energy, and by Argonne National Laboratorys Division of Educational Programs, under Contract No. W-31-109-ENG-38. Thanks are extended to Alek Pyzik of Dow Chemical USA, who provided the material for this research and arranged for the postprocessing heat treatments. Thanks to Nestor Zaluzec at Argonne National Laboratory for performing the XEDS experiments, to Craig Sperry for assistance in monitoring the experiments, and to Antonio R. de Arellano-López for his assistance in reviewing the manuscript ...

May 15, 2012. Follow-up Data from EVOLVE Trial Presented at EuroPCR; Trial is Evaluating Next-Generation Everolimus-Eluting Platinum Chromium Coronary Stent with Ultra-Thin Bioabsorbable Abluminal Polymer. Boston Scientific Corporation (NYSE: BSX) announces that the SYNERGY™ Everolimus-Eluting Bioabsorbable Polymer-Coated Platinum Chromium Coronary Stent System demonstrated non-inferior results in treating de novo coronary artery lesions at one year compared to the PROMUS Element™ Everolimus-Eluting Platinum Chromium Stent System in the EVOLVE First Human Use Trial. The trial reported one-year clinical and six-month intravascular ultrasound (IVUS) outcomes data, evaluating the safety and effectiveness of the bioabsorbable abluminal polymer-coated SYNERGY Stent. Results were presented today at the annual EuroPCR Scientific Program in Paris by Stefan Verheye, M.D., Ph.D., F.E.S.C., senior interventional cardiologist at the Antwerp Cardiovascular Institute, ZNA Middelheim Hospital, ...

DIN 54900-2 : German Language - TESTING OF THE COMPOSTABILITY OF POLYMERIC MATERIALS - PART 2: EVALUATION OF THE COMPLETE BIODEGRADABILITY OF POLYMERIC MATERIALS IN LABORATORY TESTS

A moisture-absorbing polymeric material is disclosed which consists of a combination of a thermoplastic material with an absorbing agent. The thermoplastic material is chosen such that when the absorbing agent is added to the thermoplastic material in the molten state and subsequently formed into a product, the absorbing agent tends to migrate towards the surface of the moisture-absorbing polymeric material to form a migration zone, wherein the absorbing agent is more highly concentrated in the surface of the polymer material than towards the interior.

Novel bioabsorbable polymeric blends are disclosed. The blends have a first component that is a polylactide polymer or a copolymer of lactide and glycolide and a second component that is poly(p-dioxanone) polymer. The novel polymeric blends provide medical devices having dimensional stability. Also disclosed are novel bioabsorbable medical devices made from these novel polymer blends, as well as novel methods of manufacture.

SINGAPORE, Sept. 26, 2011 /CNW/ -- Novus Scientific Announces the Worlds 1st Long-Term Absorbable Mesh as an Alternative to Non-Absorbable Synthetic Mesh.

A stent is fabricated utilizing a polymer that is selected for its tendency to degrade from the surface inwardly rather than undergo bulk erosion so as to substantially reduce the risk of large particles becoming detached and being swept downstream. Such polymer is hydrophobic yet has water-labile linkages interconnecting the monomers. Ester or imide bonds are incorporated in the polymer to render the surface degrading materials suitable for use in stent applications. The stent may be coated with such polymer or may be wholly formed therefrom.

The hot deformation characteristics of AZ31 magnesium alloy rod extruded at temperatures of 300 °C, 350 °C and 450 °C have been studied in compression. The extruded material had a fiber texture with parallel to the extrusion axis. When extruded at 450 °C, the texture was less intense and the direction moved away from the extrusion axis. The processing maps for the material extruded at 300 °C and 350 °C are qualitatively similar to the material with near-random texture (cast-homogenized) and exhibited three dynamic recrystallization (DRX) domains. In domains #1 and #2, prismatic slip is the dominant process and DRX is controlled by lattice self-diffusion and grain boundary self-diffusion, respectively. In domain #3, pyramidal slip occurs extensively and DRX is controlled by cross-slip on pyramidal slip systems. The material extruded at 450 °C exhibited two domains similar to #1 and #2 above, which moved to higher temperatures, but domain #3 is absent. The results are interpreted in terms of the

Metal-induced artifacts in computed tomography and magnetic resonance imaging: comparison of a biodegradable magnesium alloy versus titanium and stainless steel ...

Metal-induced artifacts in computed tomography and magnetic resonance imaging: Comparison of biodegradable magnesium alloy versus titanium and stainless steel ...

Your personal information will never be sold or rented to another party, in accordance with our Privacy Policy. ofXian XYMCO Magnesium Alloy Materials Co., Ltd

Based on the frame work of continuum damage mechanics, a research work of anisotropic damage evolution in warm stamping process of magnesium alloy

Just $13.92,buy AuGlamour F100C Zinc Magnesium Alloy Metal Dynamic Driver In-ear Earphones Ear-hook HiFi Stereo Earbuds with Mic and In-line Control online shopping at Gearbest Australia Mobile.

TM 1-1500-204-23-6 Table 4-7. Identification of Magnesium Alloys Commercial designation Current DOW1 ASTM2 AMC3 specification Conditions Sheet and Plate FSI AX31A C52S QQ-M-44 O (Fully Annealed) H24 (Strain Hardened Partially Annealed) H26 (Strain Hardened Partially Annealed) AX31B O (Fully Annealed) H24 (Strain Hardened Partially Annealed) Rods, Bars, and Shapes JI AZ61A C57S QQ-M-31 As Extruded FSI AZ31B C52S QQ-M-31 As Extruded M MIA 3S QQ-M-31 As Extruded 01 AZ80A C58S QQ-M-31 As Extruded Tubing FSI AX31 A C52S WW-T-825 JI AZ61A C57S WW-T-825 M MIA 3S WW-T-825 Commercial designation Current DOW ASTM AMC specification Type Temper Castings H A263A 265 QQ-M-56 Sand AC (As Cast) HT (Heat-Treated and Aged) ACS (As Cast and Stabilized) HTS (Heat-Treated and Stabilized) M MIB 403 QQ-M-56 Sand AC C A292A 260 QQ-M-56 Sand AC HT HTA ACS HTS A291 QQ-M-56 Sand AC HT HTA See footnotes at end of table. 4-15 ...

According to Xiaomi, the chassis has an internal magnesium alloy structure encased in three layers of graphite. This gives the Mi 3 a solid feel and a metallic appearance. The sandblast finish further helps to keep the Mi 3 looking clean even after using it for a week; fingerprints and smudges arent obvious and to most, you probably cant spot it. ...

The Vanguard ALTA PH-123V magnesium alloy video head is a fluid video head that includes a spring-loaded counterbalance system and a fine-tuning front to back.

Buy Panasonic Toughbook CF-53AAGBX1M 14' LED Notebook - Intel Core i5 i5-2520M 2.50 GHz - Magnesium Alloy with fast shipping and top-rated customer service. Once you know, you Newegg!

The Absorb stent is a significant advance in the way that coronary artery disease can be treated, said Philippe L.-LAllier, M.D., director, interventional cardiology, Montreal Heart Institute. Its novel technology means that once the stent has dissolved, the treated artery can pulse and flex as demands on the heart change with everyday activities. It also means physicians can more easily offer their patients other treatment options if necessary in a patients future. With Health Canadas approval of the Absorb bioresorbable stent, Abbott plans to offer the innovative device to Canadian hospitals nationwide starting this summer. Alberta resident, Cynthia Gibeau, 60, was treated with the Absorb bioresorbable heart stent three years ago through a special access program after she was diagnosed with blockages in her coronary arteries. When I was told that I could receive a stent that would disappear once it had done its job, I felt so relieved, said Cynthia. Its been three years since the ...

ACC 2017, 3/30/2017 - Poor Outcomes for Bioresorbable Stents in Small Coronary Arteries WATCH VIDEO: Bioresorbable Stent Comparable to Xience at Two Years, With Concerns Stephen Ellis, M.D., professor of medicine and director of interventional cardiology at Cleveland Clinic, discusses the two year outcomes of the ABSORB III trial of Absorb vs. Xience.…

Abbotts Bioabsorbable Stent Technology Holds Promise asFuture-Genera...ABBOTT PARK Ill. March 24 2007 /PRNewswire-FirstCall/ --Abbott tod... The encouraging results from the first 30 patients of ABSORBsuggest ...The single MACE event reported was a non-Q-wave myocardialinfarction.......,Abbott,Announces,Positive,Six-Month,Results,From,the,Worlds,First,Clinical,Trial,of,a,Fully,Bioabsorbable,Drug-Eluting,Coronary,Stent,medicine,advanced medical technology,medical laboratory technology,medical device technology,latest medical technology,Health

Intraluminal prostheses and methods of impregnating same with pharmacological agents for delivery within a body of a subject are provided. An intraluminal prosthesis comprising polymeric material is immersed in a mixture of carrier fluid and pharmacological agent(s). The mixture of carrier fluid and pharmacological agent is pressurized for a time sufficient to cause the polymeric material of the intraluminal prosthesis to swell such that the carrier fluid and pharmacological agent at least partially penetrate the swollen polymeric material. Pressure is then removed such that the carrier fluid diffuses out of the swollen polymeric material and such that a predetermined amount of the pharmacological agent remains elutably trapped within the polymeric material.

Contemporary reports by Polish authors on the application of mass spectrometric methods for the elucidation of the subtle molecular structure of biodegradable polymers and their degradation products will be presented. Special emphasis will be given to natural aliphatic (co)polyesters (PHA) and their synthetic analogues, formed through anionic ring-opening polymerization (ROP) of b-substituted b-lactones. Moreover, the application of MS techniques for the evaluation of the structure of biodegradable polymers obtained in ionic and coordination polymerization of cyclic ethers and esters as well as products of step-growth polymerization, in which bifunctional or multifunctional monomers react to form oligomers and eventually long chain polymers, will be discussed. Furthermore, the application of modern MS techniques for the assessment of polymer degradation products, frequently bearing characteristic end groups that can be revealed and differentiated by MS, will be discussed within the context of ...